He doesn’t think it’s a critical market sensitive milestone, but as a retail shareholder with a simple mind; it upgrades us to a new category within the industry and hopefully we’ll get some renewed recognition of dosing our molecules in humans instead of in the lab/animals. This recognition will hopefully be two fold - sharemarkets and industry.
But I will take his advice hint/advice to back off from sweating the small stuff and let the team get on with the excellent science and potential of the platform - which is the reason why we are all still here
Rohan said it has been the best 6 months of scientific breakthroughs they had - will check back with you all at the AGM!
Ann: Phelan-McDermid Syndrome & CNS platform presentation, page-30
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $629.9M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 12.5¢ | $919.8K | 7.025M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12715 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 276517 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PYC (ASX) Chart |